When the reboot of the TV sitcom Roseanne briefly graced our screens earlier this year, before its ignominious exit, it featured something that made me sit up and take notice: the patriarch of the Conner family, Dan Conner, played by John Goodman, was depicted in bed wearing the full face... Show More
If I said the company name Phosphagenics to you, would it ring a bell? Unless you really know the Life Sciences sector of the ASX really well, probably not. What if I said to you that this was the Melbourne-based company where, in 2013, it was revealed that then CEO... Show More
Last week I published a report on a great Life Sciences company out of Singapore called Invitrocue. Singapore is one of the finest places a global traveler could find to do Life Sciences, ranking probably the seventh most-productive Life Sciences jurisdiction on the planet in terms of the amount of... Show More
Often in Life Sciences people speak of the 'Holy Grail' as something that everyone in a particular field is looking for and will be very pleased when it is found. It's an unusual term to use given that most people in Life Sciences either aren't Christian or aren't in touch... Show More
One of the more impressive re-brandings of a Life Science company that I've seen in recent years is Kazia Therapeutics, formerly Novogen. This company changed its name in late 2017 to reflect the acquisition from Genentech of an impressive new lead compound called GDC-0084, for the treatment of glioblastoma. We... Show More
Every now and then when people ask me about building a portfolio of Life Science companies, I tell them that having a regenerative medicine stock in the portfolio is probably a good idea because we're going into a boom for that field globally. In July last year we at NDF... Show More
Just over eighteen months ago, in July 2016, I published an article headlined 'The Coming Boom in Life Sciences, Down Under' in which I suggested that Australia was on the way to a boom for its biotech and medical device sector. I argued that all the elements of that coming... Show More
One of the more straightforward ways to make money in the pharmaceuticals game is to reformulate someone else's drug once it is off patent. To develop a new drug these days will likely costs a large pharma company more than a billion US dollars and well in excess of ten... Show More
Want a sure-fire way to make money in biotech and medical device stocks? There is none. There are, however, certain things you can do to maximise your chances of success. I have been arguing lately that one of the better ways to do that is by buying stock in companies... Show More
Today we've initiated coverage on Patrys, a Melbourne-based company that may have one of the world's first cell-penetrating antibodies for the treatment of cancer. Show More
